The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
Open accessAbstract
Docetaxel is a standard chemotherapy for patients with metastatic prostate cancer. However, the response is rather limited and not all of the patients benefit from this treatment. To uncover key mechanisms of docetaxel insensitivity in prostate cancer, we have established docetaxel-resistant sublines. In this study, we report that docetaxel-resistant cells underwent an epithelial-to-mesenchymal transition during the selection process, leading to diminished E-cadherin levels and up-regulation of mesenchymal markers. Screening for key regulators of an epithelial phenotype revealed a significantly reduced expression of microRNA (miR)-200c and miR-205 in docetaxel-resistant cells. Transfection of either microRNA (miRNA) resulted in re-expression of E-cadherin. Functional assays confirmed reduced adhesive and increased invasive and migratory abilities. Furthermore, we detected an increased subpopulation with stem cell-like properties in resistant cells. Tissue microarray analysis revealed a reduced E-cadherin expression in tumors after neoadjuvant chemotherapy. Low E-cadherin levels could be linked to tumor relapse. The present study uncovers epithelial-to-mesenchymal transition as a hallmark of docetaxel resistance. Therefore, we suggest that this mechanism is at least in part responsible for chemotherapy failure, with implications for the development of novel therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Prospective Identification of Tumorigenic Prostate Cancer Stem Cells
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,820
Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., & García de Herreros, A. (2000) · Nature Cell Biology · doi:10.1038/35000034 · Cited by 2,666
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
A causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424
Patrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J. G., Chandra, D., Zhou, J., Claypool, K., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209327 · Cited by 968
Detre, S., Saclani Jotti, G., & Dowsett, M. (1995) · Journal of Clinical Pathology · doi:10.1136/jcp.48.9.876 · Cited by 880
CD133, a novel marker for human prostatic epithelial stem cells
Richardson, G. D., Robson, C. N., Lang, S. H., Neal, D. E., Maitland, N. J., & Collins, A. T. (2004) · Journal of Cell Science · doi:10.1242/jcs.01222 · Cited by 770
E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer
Schmalhofer, O., Brabletz, S., & Brabletz, T. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9179-y · Cited by 765
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S., & Sarkar, F. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012445 · Cited by 411
microRNA-205 Regulates HER3 in Human Breast Cancer
Iorio, M. V., Casalini, P., Piovan, C., Di Leva, G., Merlo, A., Triulzi, T., Ménard, S., Croce, C. M., & Tagliabue, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2920 · Cited by 365
Childs, G., Fazzari, M., Kung, G., Kawachi, N., Brandwein-Gensler, M., McLemore, M., Chen, Q., Burk, R. D., Smith, R. V., Prystowsky, M. B., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080731 · Cited by 364
Gandellini, P., Folini, M., Longoni, N., Pennati, M., Binda, M., Colecchia, M., Salvioni, R., Supino, R., Moretti, R., Limonta, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2894 · Cited by 358
Suppression of cell growth and invasion by miR-205 in breast cancer
Wu, H., Zhu, S., & Mo, Y.-Y. (2009) · Cell Research · doi:10.1038/cr.2009.18 · Cited by 358
Sun, Y., Wang, B.-E., Leong, K. G., Yue, P., Li, L., Jhunjhunwala, S., Chen, D., Seo, K., Modrusan, Z., Gao, W.-Q., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3004 · Cited by 357
Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics
Calcagno, A. M., Salcido, C. D., Gillet, J.-P., Wu, C.-P., Fostel, J. M., Mumau, M. D., Gottesman, M. M., Varticovski, L., & Ambudkar, S. V. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq361 · Cited by 279
Soltermann, A., Tischler, V., Arbogast, S., Braun, J., Probst-Hensch, N., Weder, W., Moch, H., & Kristiansen, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0935 · Cited by 269
Nalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024099 · Cited by 256
Latifi, A., Abubaker, K., Castrechini, N., Ward, A. C., Liongue, C., Dobill, F., Kumar, J., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23199 · Cited by 243
The Role of CD133 in Normal Human Prostate Stem Cells and Malignant Cancer-Initiating Cells
Vander Griend, D. J., Karthaus, W. L., Dalrymple, S., Meeker, A., DeMarzo, A. M., & Isaacs, J. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-3084 · Cited by 237
Jurmeister, S., Baumann, M., Balwierz, A., Keklikoglou, I., Ward, A., Uhlmann, S., Zhang, J. D., Wiemann, S., & Sahin, Ö. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06212-11 · Cited by 229
Zhu, M., & Kyprianou, N. (2010) · The FASEB Journal · doi:10.1096/fj.09-136994 · Cited by 226
Armstrong, A. J., Garrett-Mayer, E., de Wit, R., Tannock, I., & Eisenberger, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2514 · Cited by 207
Bhatnagar, N., Li, X., Padi, S. K. R., Zhang, Q., Tang, M.-S., & Guo, B. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.85 · Cited by 203
Xu, Y., Brenn, T., Brown, E. R. S., Doherty, V, & Melton, D. W. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.568 · Cited by 202
Sayan, A. E., Griffiths, T. R., Pal, R., Browne, G. J., Ruddick, A., Yagci, T., Edwards, R., Mayer, N. J., Qazi, H., Goyal, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902042106 · Cited by 192
Xie, Y., Xu, K., Linn, D. E., Yang, X., Guo, Z., Shimelis, H., Nakanishi, T., Ross, D. D., Chen, H., Fazli, L., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707773200 · Cited by 189
Regulation of vimentin by SIP1 in human epithelial breast tumor cells
Bindels, S., Mestdagt, M., Vandewalle, C., Jacobs, N., Volders, L., Noël, A., Roy, F. V., Berx, G., Foidart, J.-M., & Gilles, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209511 · Cited by 182
Lang, S. H., Hyde, C., Reid, I. N., Hitchcock, I. S., Hart, C. A., Gordon Bryden, A. A., Villette, J., Stower, M. J., & Maitland, N. J. (2002) · The Prostate · doi:10.1002/pros.10088 · Cited by 170
Prostate Stem Cell Antigen: A Jekyll and Hyde Molecule?
Saeki, N., Gu, J., Yoshida, T., & Wu, X. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3169 · Cited by 170
Ploussard, G., Terry, S., Maillé, P., Allory, Y., Sirab, N., Kheuang, L., Soyeux, P., Nicolaiew, N., Coppolani, E., Paule, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1447 · Cited by 161
Kim, M. A., Lee, H. S., Lee, H. E., Kim, J., Yang, H., & Kim, W. H. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03247.x · Cited by 140
Schliekelman, M. J., Gibbons, D. L., Faça, V. M., Creighton, C. J., Rizvi, Z. H., Zhang, Q. H., Wong, C., Wang, H., Ungewiss, C., Ahn, Y., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0964 · Cited by 138
Yang, C., Zeisberg, M., Lively, J. C., Nyberg, P., Afdhal, N. H., & Kalluri, R. (2003) · PubMed · Cited by 130
Zemskova, M., Sahakian, E., Bashkirova, S., & Lilly, M. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709479200 · Cited by 129
Dubrovska, A., Elliott, J., Salamone, R. J., Kim, S., Aimone, L. J., Walker, J. R., Watson, J., Maira, S.-M., García-Echeverría, C., Cho, C. Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1601 · Cited by 121
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells
Patterson, S. G., Wei, S., Chen, X., Sallman, D. A., Gilvary, D. L., Zhong, B., Pow‐Sang, J. M., Yeatman, T., & Djeu, J. Y. (2006) · Oncogene · doi:10.1038/sj.onc.1209632 · Cited by 117
Sowery, R. D., Hadaschik, B. A., So, A., Zoubeidi, A., Fazli, L., Hurtado‐Coll, A., & Gleave, M. E. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07618.x · Cited by 112
Black, P. C., Brown, G. A., Inamoto, T., Shrader, M., Arora, A., Siefker-Radtke, A. O., Adam, L., Theodorescu, D., Wu, X., Munsell, M. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1593 · Cited by 109
Agiostratidou, G., Hulit, J., Phillips, G. R., & Hazan, R. B. (2007) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-007-9044-6 · Cited by 92
Puhr, M., Santer, F. R., Neuwirt, H., Susani, M., Nemeth, J. A., Hobisch, A., Kenner, L., & Čulig, Z. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0806 · Cited by 84
Self-citationPIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21
Hoefer, J., Schäfer, G., Klocker, H., Erb, H. H. H., Mills, I. G., Hengst, L., Puhr, M., & Čulig, Z. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.01.026 · Cited by 82
Self-citationSong, H., & Bu, G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.020 · Cited by 69
Induction of Clusterin by AKT—Role in Cytoprotection against Docetaxel in Prostate Tumor Cells
Zhong, B., Sallman, D. A., Gilvary, D. L., Pernazza, D., Sahakian, E., Fritz, D., Cheng, J. Q., Trougakos, I. P., Sheng, W., & Djeu, J. Y. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0880 · Cited by 56
Cited by
Tackling the cancer stem cells — what challenges do they pose?
Pattabiraman, D. R., & Weinberg, R. A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4253 · Cited by 990
Controversies around epithelial–mesenchymal plasticity in cancer metastasis
Williams, E. D., Gao, D., Redfern, A., & Thompson, E. W. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0213-x · Cited by 451
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Szeto, C.-C., & Li, P. K.-T. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.50 · Cited by 80
Metadata
- Authors
- Puhr, M., Hoefer, J., Schäfer, G., Erb, H. H. H., Oh, S. J., Klocker, H., Heidegger, I., Neuwirt, H., & Culig, Z.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 181
- Issue
- 6
- Pages
- 2188-2201
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2079113237
- Cited by
- 263
- References
- 50
- FWCI
- 17.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.